Clinical and genomic evaluations of a persistent fatal SARS-CoV-2 infection in a goods syndrome patient: a case report

Abstract The coronavirus disease of 2019 (COVID-19) resulted from an infection by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) which is the main cause of acute respiratory distress syndrome (ARDS) in global population from 2019 on. It may contribute to higher rate of death among the patients with immunodeficiency based on recent reports. In addition, Good syndrome (GS) as a result of thymoma removal might cause in some long-lasting microbial infections. We described clinical aspects and viral mutations on a case of GS suffering from COVID-19. A 46-year-old man with fever, common respiratory disease symptoms and positive COVID-19 polymerase chain reaction (PCR) test, with the history of thymoma removal surgery was admitted to Masih Daneshvari Hospital, Tehran, Iran. Lung radiographs and oxygen saturation measurement disclosed considerable implication resulted in application of several anti-microbial medication. The delta variant (B.1.617.2 (21 J Clade)) was the strain isolated from the patient by sequencing methods done by the COVID-19 National Reference Laboratory (CNRL), Pasteur Institute of Iran, while the dominant strain circulated mostly among population was Omicron (B.1.1.529) at the time of sampling. Unfortunately, the patient had passed away a month later by sudden respiratory failure progressed in refractory septic shock. Despite the fact that opportunistic infections may lead the GS patients to a major health problematic condition, unusual persistent of infections such as non-dominant variant of SARS-Cov-2 could be observed through the disease timeline. Therefore, a fully screening of thymoma plus intra-host evolution monitoring of SARS-CoV-2 is highly recommended in immunocompromised patients..

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:24

Enthalten in:

BMC infectious diseases - 24(2024), 1 vom: 19. Feb.

Sprache:

Englisch

Beteiligte Personen:

Tabarsi, Payam [VerfasserIn]
Maleki, Ali [VerfasserIn]
Abtahian, Zahra [VerfasserIn]
khabbaz, Alieh [VerfasserIn]
Fereydouni, Zahra [VerfasserIn]
Rezaie, Jahangir [VerfasserIn]
Tavakoli, Mahsa [VerfasserIn]
Sanati, Parastoo Yektay [VerfasserIn]
Salehi-Vaziri, Mostafa [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Autoimmune diseases
COVID-19
Good syndrome
SARS-CoV-2

Anmerkungen:

© The Author(s) 2024

doi:

10.1186/s12879-024-09105-6

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

SPR054825172